Long-term Results from an Open-label Extension Study of Atacicept for the Treatment of IgA Nephropathy
-
Register
- Member - Free!
- Subscriber - Free!
Already registered?
Log in now.
Explore the results of the ORIGIN Phase 2b study and open label extension in this video abstract
This video abstract was supported by Vera Therapeutics
Key:
Complete
Next
Failed
Available
Locked
Long-term Results from an Open-label Extension Study of Atacicept for the Treatment of IgA Nephropathy
Open to view video.
Open to view video.